Aims: Colorectal carcinoma (CRC) is one of the most common cancers worldwide and is associated with significant morbidity and mortality. Histopathology plays a crucial role in the diagnosis, prognostication and treatment planning of CRC. In addition to well‐established morphological parameters such as tumour budding, grade and histopathological subtypes, the interaction between tumour cells and adipose tissue has gained increasing attention.Methods and results: The frequency of direct proximity between cancer cells and adipocytes, termed Stroma Areactive Invasion Front Areas (SARIFA), was assessed in a multicentre cohort of 1,298 patients with pT3/pT4 CRC. The prognostic impact of SARIFA was evaluated, with a particular focus on its relationship with established histopathological parameters. SARIFA was associated with adverse clinicopathological features and served as an indicator of poor prognosis across all survival metrics in the overall cohort (disease‐specific survival [DSS]; P < 0.001). This prognostic value remained significant across all pTNM stages (e.g. DSS in pT3, pN0, pN1/2, pM0 CRC; P < 0.001, respectively) and identified additional adverse prognostic subgroups within tumour budding and grade categories (DSS, P < 0.001, respectively) and within histopathological subtypes. In multivariable analyses, including pTNM stage and the aforementioned histopathological parameters, SARIFA remained a highly significant prognostic factor (DSS P < 0.001, hazard ratio: 1.73).Discussion: Our study confirms the high prognostic relevance of SARIFA across key clinicopathological subgroups of CRC and highlights its value as a meaningful complement to established morphological parameters. Given its ability to provide additional prognostic insights, our findings advocate for its inclusion in pathology reports to improve risk assessment and clinical management.
Personalized medicine is guided by an expanding array of molecular targets. This study investigates whether larger next-generation sequencing (NGS) gene panels (> 1 Mb) yield more clinically relevant therapy options in molecular tumor boards (MTB) compared to smaller panels. We analyzed 281 consecutive patients using a 430-gene DNA panel (1.3 Mb) combined with a RNA-fusion panel and compared the findings to a 185-gene DNA panel (618 kb). Molecular alterations were detected in 97.2 % of tumors with either oncogenic variants and/or gene fusions. Among these, 170 (60.5 %) received a molecular-stratified therapy recommendation from the local MTB. Only 8.8 % depended on the expanded 430-gene DNA panel, and additionally identified actionable variants in five additional genes. High TMB alone enabled 4.1 % of MTB recommendations. Our findings indicate that sufficient genomic coverage in DNA panels is essential for reliable TMB calculation, defining a minimal standard for genomic cancer care.